Accessibility Menu
Prothena Plc Stock Quote

Prothena Plc (NASDAQ: PRTA)

$10.22
(-1.5%)
-0.15
Price as of October 21, 2025, 4:00 p.m. ET

KEY DATA POINTS

Current Price
$10.22
Daily Change
(-1.5%) $0.15
Day's Range
$10.18 - $10.61
Previous Close
$10.22
Open
$10.37
Beta
1.42
Volume
1
Average Volume
901,575
Market Cap
549.9M
Market Cap / Employee
$10.21M
52wk Range
$4.32 - $18.88
Revenue
-
Gross Margin
0.65%
Dividend Yield
N/A
EPS
-$5.63
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Prothena Plc Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
PRTA-38.09%-13.58%-2.88%+44%
S&P+15.06%+95.03%+14.29%+371%

Prothena Plc Company Info

Prothena Corp. Plc is a clinical-stage neuroscience company. It focuses on the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$4.42M-96.7%
Gross Profit$3.54M-97.3%
Gross Margin80.02%-19.3%
Market Cap$326.73M-70.6%
Market Cap / Employee$2.00M0.0%
Employees163-5.8%
Net Income-$125.77M-288.0%
EBITDA-$51.12M-186.3%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$371.44M-34.2%
Accounts Receivable$0.00M-100.0%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$6.93M-27.4%
Short Term Debt$2.85M10.6%

Ratios

Q2 2025YOY Change
Return On Assets-58.00%-50.5%
Return On Invested Capital-22.33%0.4%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$50.28M-413.4%
Operating Free Cash Flow-$50.19M-410.0%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book1.681.391.370.75-66.18%
Price to Sales6.755.514.8331.60504.18%
Price to Tangible Book Value1.681.391.370.75-66.18%
Enterprise Value to EBITDA-5.98-4.45-4.000.68-93.07%
Return on Equity-22.9%-23.3%-23.5%-66.9%663.79%
Total Debt$11.49M$10.84M$10.20M$9.78M-19.28%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.